DCLK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tofacitinib (SCHEMBL322753)	1.00	2/20
Tofacitinib (SCHEMBL1120705)	1.00	2/20
Tofacitinib (SCHEMBL1374185)	1.00	2/20
SCHEMBL2323500	0.85	2/20
SCHEMBL3065509	0.85	2/20
SCHEMBL2320931	0.80	2/20
SCHEMBL3683647	0.80	2/20
SCHEMBL4061567	0.78	2/20
SCHEMBL1846276	0.78	2/20
SCHEMBL4069759	0.78	2/20
SCHEMBL2319641	0.77	2/20
SCHEMBL3678056	0.77	2/20
SCHEMBL4062773	0.77	2/20
SCHEMBL4070029	0.77	2/20
Hydrochloric Acid (SCHEMBL4066429)	0.76	2/20
SCHEMBL4068174	0.76	2/20
SCHEMBL2148397	0.75	2/20
SCHEMBL353500	0.75	2/20
SCHEMBL2319231	0.75	2/20
SCHEMBL3061573	0.75	2/20

Clinical trials — most relevant to DCLK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma	PHASE2/PHASE3	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
DC Vaccine Combined With CIK Cells in Patients With SCLC	PHASE1/PHASE2	UNKNOWN
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer	PHASE2	UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers	PHASE1/PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	PHASE1	COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors	EARLY_PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)	nan	UNKNOWN
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy	nan	COMPLETED
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer	nan	ACTIVE_NOT_RECRUITING
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor	nan	UNKNOWN
PCD New Gene Discovery	nan	COMPLETED
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
High-Risk Breast Duct Epithelium	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DCLK3 binder may also engage these)

Protein	Name	Similarity
Q8BWQ5	—	1.000	Q8BWQ5 →
Q63553	—	0.993	Q63553 →
Q0DCT8	—	0.991	Q0DCT8 →
Q8VDU5	—	0.989	Q8VDU5 →
SNRK	SNF-related serine/threonine-protein kinase	0.989	landscape →
Q5TKR9	—	0.989	Q5TKR9 →
MYLK2	Myosin light chain kinase 2, skeletal/cardiac muscle	0.989	landscape →
A2YBX5	—	0.988	A2YBX5 →
Q3UIZ8	—	0.988	Q3UIZ8 →
Q9LFA2	—	0.988	Q9LFA2 →
F4ICB6	—	0.987	F4ICB6 →
Q9Z1J2	—	0.987	Q9Z1J2 →
Q9SB51	—	0.987	Q9SB51 →
Q8WML3	—	0.987	Q8WML3 →
Q6NTJ3	—	0.987	Q6NTJ3 →
Q8K4K7	—	0.987	Q8K4K7 →
Q2PFD7	—	0.987	Q2PFD7 →
Q9UPV7	—	0.987	Q9UPV7 →
P20689	—	0.987	P20689 →
F4J6F6	—	0.986	F4J6F6 →
Q24K09	—	0.986	Q24K09 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.986	landscape →
Q66HE5	—	0.986	Q66HE5 →
Q924U5	—	0.986	Q924U5 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.986	landscape →
DNMT1	DNA (cytosine-5)-methyltransferase 1	0.986	landscape →
Q9LE81	—	0.986	Q9LE81 →
Q60700	—	0.986	Q60700 →
F4HYG2	—	0.986	F4HYG2 →
Q5R8Z4	—	0.986	Q5R8Z4 →